Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: george who wrote (653)	12/11/1997 12:59:00 PM
From: Cisco	Respond to of 1894

George, Isn't this new Public Relations from AccuMed great! If they had this two months ago we would probably still be holding a $3.00 stock. This was my biggest concern with the company. Your correct, it appears it has been fixed. Hard Wired?? I have this new terminal which is about the size of pager that I wear. I was putting up the Christmas tree when I saw the release come out.<g> Cisco

To: george who wrote (653)	12/11/1997 1:14:00 PM
From: Frank Buck	Read Replies (1) \| Respond to of 1894

Congratulations are in order to Dana Winrow, MD Investor Relations for AccuMed International, Inc's recent press release; "AccuMed Demonstrates Increased Productivity & Improved Screening of Monolayer Slides" The release is a sensational power-punch. Not only does it inform but it also is linked and shows up as big as can be in Cytyc Corp. (CYTC) and Autocyte Inc. (ACYT) news columns. Any shareholder or perspective shareholder looking at those two companies will certainly read about AccuMed and the AcCell/TracCell Systems. That's what I call getting the most bang for your advertising dollars. A triple whammy! I wonder if there are any other presents under the AccuMed Christmas tree for good little shareholders?

To: george who wrote (653)	12/12/1997 11:04:00 PM
From: Cisco	Read Replies (2) \| Respond to of 1894

To all, I received a communication from AccuMed tonight in answer to two questions we have been discussing on this thread in recent days. The first regarded the implementation of AccuMed's new investor relation program. The second discussed the impact AccuMed would feel if NeoPath received FDA approval to use their AutoPap System as a primary screener. The reply came from Dana Winrow, M.D., Investor Relations, AccuMed International, Inc. New Investor Relations Program ®We are in the process of implementing a new Investor Relations program at AccuMed that will involve greater communication with the Company's shareholders and the investment community at large. We will soon be offering an e-mail-based mailing list for press releases and other timely Company information. The AccuMed website - accumed.com - will be updated shortly; we plan to make informative documents, such as the transcript of the December 5th conference call and analyst reports, available online.¯ Impact of a Primary Screener ®If NeoPath's device were to be approved by the FDA for primary screening, the need for AccuMed's AcCell/TracCell system will increase. The NeoPath system will necessitate an increase in productivity to reduce the overall cost and to provide more time for quality review, since 70+% of the slides that would be subject to human review following NeoPath instrument processing are considered by the machine to be "suspicious" or of "higher risk".¯ I hope you will find this information helpful. Cisco